Duolingo Inc vs Zimmer Biomet Holdings Inc — how do they compare? Duolingo Inc trades at $148.83 (market cap $7.08B), while Zimmer Biomet Holdings Inc trades at $88.94 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.4× Duolingo Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| DUOL | ZBH | |
|---|---|---|
Market Cap | $7.08B | $16.95B |
Volume | 729,171 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $341.08 | $103.98 |
52-Week Low | $90.03 | $79.58 |
Typical Hold Time | 137 Days | 89 Days |
Enterprise Value | $5.85B | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $150.50, down 0.8% on the day, as the stock consolidates near key resistance at $151. The company demonstrates strong fundamental momentum with revenue reaching $1.04 billion in 2025 and net income surging to $414 million, representing a robust 39.9% margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $0.66 exceeding the $0.604 forecast. Technical indicators show a bullish moving average alignment while RSI levels suggest potential near-term consolidation.
Duolingo presents a compelling growth story with accelerating profitability and strong user engagement, though valuation multiples remain elevated. Key risks include increased competition in edtech and insider selling activity. Analyst consensus leans cautious with a $140.63 price target below current levels, suggesting potential near-term headwinds despite the company's operational excellence.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →